These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 21119726)
1. An audience with Thomas Lönngren. Interview by Asher Mullard. Lönngren T Nat Rev Drug Discov; 2010 Dec; 9(12):912. PubMed ID: 21119726 [No Abstract] [Full Text] [Related]
2. An audience with... Thomas Lönngren. Lönngren T Nat Rev Drug Discov; 2006 Mar; 5(3):182. PubMed ID: 16557656 [No Abstract] [Full Text] [Related]
3. An audience with Abraham Thomas. Interview by Asher Mullard. Thomas A Nat Rev Drug Discov; 2011 Feb; 10(2):90-1. PubMed ID: 21283097 [No Abstract] [Full Text] [Related]
4. An audience with Guido Rasi. Interview by Asher Mullard. Rasi G Nat Rev Drug Discov; 2012 Mar; 11(3):182. PubMed ID: 22378260 [No Abstract] [Full Text] [Related]
5. David Urdal. Interview with Asher Mullard. Nat Rev Drug Discov; 2011 Oct; 10(11):806-7. PubMed ID: 22037031 [No Abstract] [Full Text] [Related]
6. Quicker drug approvals on the way for Europe. Davidson S Nat Biotechnol; 2001 Sep; 19(9):798-9. PubMed ID: 11533626 [No Abstract] [Full Text] [Related]
8. Gigi Hirsch. Interview by Asher Mullard. Hirsch G Nat Rev Drug Discov; 2014 Jan; 13(1):14. PubMed ID: 24378793 [No Abstract] [Full Text] [Related]
9. An audience with... Susan Desmond-Hellmann. Interview by... Asher Mullard. Desmond-Hellmann S Nat Rev Drug Discov; 2011 Mar; 10(3):170. PubMed ID: 21358729 [No Abstract] [Full Text] [Related]
10. An audience with… Henry Chesbrough. Interview by Asher Mullard. Chesbrough H Nat Rev Drug Discov; 2013 May; 12(5):338-9. PubMed ID: 23598507 [No Abstract] [Full Text] [Related]
11. Richard Bergström. Interview by Asher Mullard. Bergström R Nat Rev Drug Discov; 2011 Jun; 10(6):408. PubMed ID: 21629284 [No Abstract] [Full Text] [Related]
12. The common technical document: the changing face of the New Drug Application. Molzon J Nat Rev Drug Discov; 2003 Jan; 2(1):71-4. PubMed ID: 12509761 [TBL] [Abstract][Full Text] [Related]
13. Paul Brown. Interview by Asher Mullard. Brown P Nat Rev Drug Discov; 2011 Sep; 10(10):726. PubMed ID: 21959279 [No Abstract] [Full Text] [Related]
14. An audience with... Gregory Lip. Interview by Asher Mullard. Lip G Nat Rev Drug Discov; 2012 Jun; 11(6):434. PubMed ID: 22653207 [No Abstract] [Full Text] [Related]
15. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage? Roman A Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322 [No Abstract] [Full Text] [Related]
16. How FDA approves biotechnology drugs. Manuel SM; Piascik P Am Pharm; 1995 May; NS35(5):14-5. PubMed ID: 7611131 [No Abstract] [Full Text] [Related]
17. Sandoz sues FDA over delay in first biogeneric approval. Fox JL Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046 [No Abstract] [Full Text] [Related]
18. Closing the drug lag for new drug submission and review in Japan: An industry perspective. Poirier AF Clin Pharmacol Ther; 2015 Nov; 98(5):486-8. PubMed ID: 26239646 [TBL] [Abstract][Full Text] [Related]
19. The application of the patent laws to the drug approval process. Coggio BD; Cerrito FD Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669 [No Abstract] [Full Text] [Related]
20. Examining Manufacturing Readiness for Breakthrough Drug Development. Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693 [No Abstract] [Full Text] [Related] [Next] [New Search]